-
Featured
Tau PET Imaging May Help Identify People with Pre-symptomatic Alzheimer’s Disease
Brain changes associated with Alzheimer’s disease can now be studied in living people. Mass General researchers imaged cognitively normal people who are destined to develop AD due to a rare genetic mutation. Their goal: to discover how soon brain changes are present before symptoms begin and how soon preventive treatments could be initiated.
-
Featured
NEJM Images in Clinical Medicine: Using Ventriculoperitoneal Shunt Placement to Treat Normal-pressure Hydrocephalus
Neurologists at Mass General explore the case of a woman who endured gait disturbance, cognitive impairment and urinary incontinence for 2 years before she was diagnosed with normal-pressure hydrocephalus and successfully treated with surgical shunting.
-
Featured
fMRI and EEG May Find Signals of Consciousness Earlier in Severe Traumatic Brain Injury Patients
The rate of misclassification of unconsciousness can be as high as 40%. A Mass General team studied using fMRI and EEG to better identify patients with unconsciousness in the ICU.
-
Researchers Identify a New Therapeutic Target for TDP-43-mediated Neurodegenerative Diseases
Loss of TDP-43 nuclear function is a major event in ALS pathogenesis and leads to widespread RNA processing alterations including reduced stathmin-2 levels. Stathmin-2 is shown to be crucial for axonal regeneration and to represent a novel therapeutic target in ALS.
-
Nuclear-import Receptors Can Dissolve Cytoplasmic Protein Aggregates Associated with Neurodegenerative Disorders Such as ALS
Massachusetts General Hospital investigators assessed the role of nuclear import receptor (NIRs) in disrupting such aggregates associated with neurodegenerative disorders, chaperoning these proteins from the cytoplasm to the nucleus and restoring their normal function, thereby rescuing the cell from degeneration.
-
Novel Immunomodulator Safe and Tolerable in Pilot Study for ALS
Building on promising data from preclinical models of ALS, physician-scientists at the Healy Center for ALS at Massachusetts General Hospital have completed the first translational step in developing a new immunomodulatory drug for ALS.
Neurology contributors
-
Brian L. Edlow, MD
Associate Director, Center for Neurotechnology and Neurorecovery (CNTR), Director, Laboratory for NeuroImaging of Coma and Consciousness (NICC), Director, Critical Care Research Neuroimaging
Recent Article
fMRI and EEG May Find Signals of Consciousness Earlier in Severe Traumatic Brain Injury Patients -
Jodi Gilman, PhD
Director of Neuroscience, Center for Addiction Medicine
Recent Article
Marijuana and the Young Brain
-
Keith A. Johnson, MD
Radiologist
Recent Article
Tau PET Imaging May Help Identify People with Pre-symptomatic Alzheimer’s Disease
-
Nagagopal Venna, MD
Director, Neurology Clinic, Director, Neuro-Infectious Diseases Clinic, Director, Academic General Neurology Fellowship Program
Recent Article
NEJM Images in Clinical Medicine: Using Ventriculoperitoneal Shunt Placement to Treat Normal-pressure Hydrocephalus
-
Yakeel T. Quiroz-Gaviria, PhD
Co-Director, MGH Multicultural Neuropsychology Program (MUNDOS)
Recent Article
Tau PET Imaging May Help Identify People with Pre-symptomatic Alzheimer’s Disease
Neuroscience Care at Mass General
Through a combination of unmatched expertise, creativity and compassion, Mass General Neuroscience relentlessly advances the fields of Neurosurgery, Neurology and Psychiatry to unleash our patients’ potential.Resource Links
